While dabbling in direct-to-consumer, Genetic Analysis AS’s focus remains on developing and commercializing “clinical-grade” gut health diagnostics, with a growing number of opportunities emerging for pharma collaboration.
Genetic Analysis Leaders On Gut Microbiota Testing, Pharma Connections And Direct-To-Consumer Scene
Genetic Analysis CEO Ronny Hermansen and Christina Casén, senior VP of clinical and medical affairs, discuss the company’s polymerase chain reaction (PCR)-based approach to gut microbiota profiling versus DNA sequencing, competitive landscape, and opportunities for supporting pharma R&D and assessing drug treatment success.
